In a clinical trial of patients with rheumatoid arthritis, treatment with a drug called upadacitinib provided greater benefits than methotrexate, the most commonly used initial therapy for rheumatoid arthritis. Upadacitinib inhibits certain proteins called Janus kinase enzymes that are involved in inflammation. It’s approved for treating patients with rheumatoid arthritis, but only after they’ve tried...
Tag: <span>rheumatoid</span>
Post
Patients with rheumatoid arthritis have an increased risk of certain types of malignancy
The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) examined rates of malignancy in patients with rheumatoid arthritis (RA), excluding non-melanoma skin cancer (NMSC), and found no difference between those newly treated with tocilizumab (TCZ) versus TNF inhibitors (TNFi). RA is a chronic inflammatory disease that affects a person’s joints, causing...
Post
Gum disease may be a key initiator of rheumatoid arthritis related autoimmunity
The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) demonstrates increased levels of gum disease, and disease-causing bacteria, in individuals at risk of rheumatoid arthritis (RA). “It has been shown that RA-associated antibodies, such as anti-citrullinated protein antibodies, are present well before any evidence of joint disease. This suggests...